TScan Therapeutics (TCRX)
Market Price (5/6/2026): $1.22 | Market Cap: $158.4 MilSector: Health Care | Industry: Biotechnology
TScan Therapeutics (TCRX)
Market Price (5/6/2026): $1.22Market Cap: $158.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 267% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -121% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -136 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1315% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 113% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1311%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1353% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -87% Key risksTCRX key risks include [1] significant clinical trial delays and regulatory hurdles for its lead programs and [2] specific efficacy and safety concerns for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 267% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -121% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -136 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1315% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 113% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1311%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1353% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -87% |
| Key risksTCRX key risks include [1] significant clinical trial delays and regulatory hurdles for its lead programs and [2] specific efficacy and safety concerns for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
TScan Therapeutics (TCRX) stock has gained about 20% since 1/31/2026 because of the following key factors:
1. Significant Clinical Milestones for the Hematologic Malignancies Program.
TScan Therapeutics achieved key advancements in its ALLOHA™ clinical program for hematologic malignancies. On February 26, 2026, the company announced the successful completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial, where patients are being treated using a new commercial-ready manufacturing process. Concurrently, the FDA cleared Investigational New Drug (IND) applications for TSC-102-A01 and TSC-102-A03, expanding the program to address a broader patient population with specific HLA types (A01:01 and A03:01). These developments, including plans to initiate Phase 1 studies for the TSC-102 candidates in the second half of 2026, underscore progress in TScan's core therapeutic area.
2. Strategic Prioritization and Enhanced Financial Stability.
TScan Therapeutics implemented a strategic prioritization, announced in November 2025, which continued to positively impact its financial outlook in 2026. The company shifted its focus to accelerate the clinical development of its heme program, specifically TSC-101, and paused further enrollment in its solid tumor PLEXI-T trial. This strategic realignment included a workforce reduction of approximately 30% (66 employees), which is projected to generate significant annual cost savings of about $45 million in both 2026 and 2027. These measures are expected to extend the company's cash runway into the second half of 2027, alleviating near-term liquidity concerns.
Show more
1. Significant Clinical Milestones for the Hematologic Malignancies Program.
TScan Therapeutics achieved key advancements in its ALLOHA™ clinical program for hematologic malignancies. On February 26, 2026, the company announced the successful completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial, where patients are being treated using a new commercial-ready manufacturing process. Concurrently, the FDA cleared Investigational New Drug (IND) applications for TSC-102-A01 and TSC-102-A03, expanding the program to address a broader patient population with specific HLA types (A01:01 and A03:01). These developments, including plans to initiate Phase 1 studies for the TSC-102 candidates in the second half of 2026, underscore progress in TScan's core therapeutic area.
2. Strategic Prioritization and Enhanced Financial Stability.
TScan Therapeutics implemented a strategic prioritization, announced in November 2025, which continued to positively impact its financial outlook in 2026. The company shifted its focus to accelerate the clinical development of its heme program, specifically TSC-101, and paused further enrollment in its solid tumor PLEXI-T trial. This strategic realignment included a workforce reduction of approximately 30% (66 employees), which is projected to generate significant annual cost savings of about $45 million in both 2026 and 2027. These measures are expected to extend the company's cash runway into the second half of 2027, alleviating near-term liquidity concerns.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 18.6% change in TCRX stock from 1/31/2026 to 5/5/2026 was primarily driven by a 22.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.02 | 1.21 | 18.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 10 | 22.6% |
| P/S Multiple | 15.7 | 15.2 | -3.2% |
| Shares Outstanding (Mil) | 130 | 130 | 0.0% |
| Cumulative Contribution | 18.6% |
Market Drivers
1/31/2026 to 5/5/2026| Return | Correlation | |
|---|---|---|
| TCRX | 18.6% | |
| Market (SPY) | 3.6% | 46.0% |
| Sector (XLV) | -5.7% | 20.3% |
Fundamental Drivers
The -37.6% change in TCRX stock from 10/31/2025 to 5/5/2026 was primarily driven by a -57.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.94 | 1.21 | -37.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 10 | 48.3% |
| P/S Multiple | 36.2 | 15.2 | -57.9% |
| Shares Outstanding (Mil) | 130 | 130 | -0.1% |
| Cumulative Contribution | -37.6% |
Market Drivers
10/31/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| TCRX | -37.6% | |
| Market (SPY) | 5.5% | 34.4% |
| Sector (XLV) | 1.6% | 19.8% |
Fundamental Drivers
The -24.6% change in TCRX stock from 4/30/2025 to 5/5/2026 was primarily driven by a -77.9% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.60 | 1.21 | -24.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 10 | 266.7% |
| P/S Multiple | 68.9 | 15.2 | -77.9% |
| Shares Outstanding (Mil) | 121 | 130 | -6.9% |
| Cumulative Contribution | -24.6% |
Market Drivers
4/30/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| TCRX | -24.6% | |
| Market (SPY) | 30.4% | 31.8% |
| Sector (XLV) | 5.3% | 25.3% |
Fundamental Drivers
The -46.7% change in TCRX stock from 4/30/2023 to 5/5/2026 was primarily driven by a -81.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 1.21 | -46.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 10 | -23.7% |
| P/S Multiple | 4.0 | 15.2 | 276.9% |
| Shares Outstanding (Mil) | 24 | 130 | -81.5% |
| Cumulative Contribution | -46.7% |
Market Drivers
4/30/2023 to 5/5/2026| Return | Correlation | |
|---|---|---|
| TCRX | -46.7% | |
| Market (SPY) | 78.7% | 19.3% |
| Sector (XLV) | 14.4% | 20.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TCRX Return | -57% | -66% | 276% | -48% | -67% | 22% | -88% |
| Peers Return | 8% | -28% | 8% | -15% | -3% | 23% | -15% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| TCRX Win Rate | 17% | 33% | 75% | 42% | 50% | 80% | |
| Peers Win Rate | 42% | 42% | 40% | 50% | 48% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 40% | |
Max Drawdowns [4] | |||||||
| TCRX Max Drawdown | -57% | -67% | 0% | -51% | -71% | -9% | |
| Peers Max Drawdown | -29% | -42% | -26% | -31% | -34% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, BMY, IOVA, CRSP, NTLA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/5/2026 (YTD)
How Low Can It Go
| Event | TCRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.1% | -18.8% |
| % Gain to Breakeven | 89.1% | 23.1% |
| Time to Breakeven | 180 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.4% | -6.7% |
| % Gain to Breakeven | 57.3% | 7.1% |
| Time to Breakeven | 8 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.1% | -24.5% |
| % Gain to Breakeven | 186.7% | 32.4% |
| Time to Breakeven | 366 days | 427 days |
In The Past
TScan Therapeutics's stock fell -47.1% during the 2025 US Tariff Shock. Such a loss loss requires a 89.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TCRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.1% | -18.8% |
| % Gain to Breakeven | 89.1% | 23.1% |
| Time to Breakeven | 180 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.4% | -6.7% |
| % Gain to Breakeven | 57.3% | 7.1% |
| Time to Breakeven | 8 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.1% | -24.5% |
| % Gain to Breakeven | 186.7% | 32.4% |
| Time to Breakeven | 366 days | 427 days |
In The Past
TScan Therapeutics's stock fell -47.1% during the 2025 US Tariff Shock. Such a loss loss requires a 89.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TScan Therapeutics (TCRX)
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
AI Analysis | Feedback
Analogy 1: "An early-stage Moderna or BioNTech, but focused on engineering T-cells to fight cancer rather than primarily developing mRNA vaccines."
Analogy 2: "Like a next-generation Gilead Sciences (Kite Pharma) or Novartis for advanced engineered T-cell cancer treatments."
AI Analysis | Feedback
- TCR-engineered T-cell therapies for hematologic malignancies: These therapies, including TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.
- TCR-engineered T-cell therapies for solid tumors: This pipeline includes candidates like TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of various solid tumor cancers.
- Vaccines for infectious diseases: The company is also developing vaccines targeting infectious diseases, such as SARS-CoV-2.
AI Analysis | Feedback
TScan Therapeutics (TCRX) is a preclinical-stage biopharmaceutical company, meaning it is focused on research and development and has not yet brought products to market for sale to individuals or healthcare providers. Therefore, its primary "customers" or revenue-generating relationships are typically with other companies through collaborations and licensing agreements.
Based on the provided information, TScan Therapeutics has a significant collaboration and license agreement with:
- Novartis Institutes for BioMedical Research, Inc. (a subsidiary of Novartis AG, symbol: NVS)
This agreement makes Novartis a major "customer" in the context of TScan Therapeutics' research, technology, and potential future product rights.
AI Analysis | Feedback
Thermo Fisher Scientific (TMO)
AI Analysis | Feedback
Gavin MacBeath, Ph.D. Chief Executive Officer Dr. MacBeath was appointed CEO in May 2023, having served as acting CEO since March 2023. He has over two decades of experience in academia and industry, including founding companies and advancing research from early-stage discovery to drug approval. Prior to TScan, he co-founded Merrimack Pharmaceuticals, serving as Senior Vice President of Discovery where he progressed several biologics through IND, Phase 1, and Phase 2 clinical development. He also served as Chief Scientific Officer at Abpro. Dr. MacBeath has co-founded three oncology companies. Jason Amello Chief Financial Officer and Treasurer Mr. Amello joined TScan as Chief Financial Officer and Treasurer in January 2024. He previously served as CFO, Treasurer, and Secretary at Candel Therapeutics, Inc. His extensive experience includes CFO and Treasurer roles at Saniona AB and Akebia Therapeutics, Inc., as well as Executive Vice President, CFO, and Treasurer of Alaunos Therapeutics, Inc. (formerly ZIOPHARM Oncology, Inc.). From 2000 to 2011, Mr. Amello held various finance leadership positions at Genzyme Corporation (acquired by Sanofi), including Senior Vice President and Chief Accounting Officer, where he advised on mergers and acquisitions, including the company's sale to Sanofi for approximately $20 billion. He also served on the Board of Directors of Acer Therapeutics, Inc. Chrystal Louis, M.D., M.P.H. Chief Medical Officer Dr. Louis joined TScan as Chief Medical Officer in April 2024. Before TScan, she was the Senior Vice President of hematology clinical development at Zentalis Pharmaceuticals, Inc. She also served as Vice President, Head of Medical Affairs at CRISPR Therapeutics, Inc. Zoran Zdraveski, J.D., Ph.D. Chief Legal and Strategy Officer and Secretary Dr. Zdraveski has served as TScan's Chief Legal and Strategy Officer and Secretary since September 2021. He brings over 20 years of legal, intellectual property, and business operations experience within the biopharmaceutical industry, with previous tenure at Alnylam Pharmaceuticals, Inc. Justin McCue, Ph.D. Chief Technology Officer Dr. McCue was appointed Chief Technology Officer in December 2023. He has over 20 years of experience in biologics and cell therapy manufacturing, encompassing process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products. Prior to joining TScan, he served as Chief Technology Officer at Avectas, and previously as Vice President of Technical Operations at Repertoire Immune Medicines.AI Analysis | Feedback
TScan Therapeutics (NASDAQ: TCRX) faces several key business risks inherent to its nature as a clinical-stage biopharmaceutical company. The most significant risk is the **uncertainty of clinical trial outcomes and regulatory approval** for its T cell receptor-engineered T cell (TCR-T) therapies. As a company whose business depends heavily on the success of its proprietary platform, the failure of any of its drug candidates, such as TSC-100, TSC-101, or those targeting solid tumors, in clinical trials or to gain regulatory approval would materially impact its share value and overall viability. The company's pipeline largely remains in early clinical stages, and the inherently speculative nature of biotechnology means most of its intellectual property is largely unproven. Its future largely hinges on the success of its lead hematologic malignancy candidate, TSC-101. Secondly, **financial health and the ongoing need for substantial additional funding** pose a critical risk. TScan Therapeutics has incurred significant losses since its inception and anticipates continuing to incur losses for several more years, with no guarantee of achieving or sustaining profitability. The company's financial challenges are highlighted by a negative earnings per share and net margin, and an Altman Z-Score in the "distress zone," indicating a potential risk of bankruptcy within two years, as of March 2026. Although TScan projects its current capital will sustain operations until the latter half of 2027, it will require substantial additional funding to complete the development and potential commercialization of its product candidates. Failure to raise sufficient capital could force the company to delay, reduce, or eliminate crucial product development programs or commercialization efforts. Finally, **intense competition and the protection of intellectual property** represent a substantial risk. TScan Therapeutics operates in a highly competitive and rapidly evolving biopharmaceutical environment. The company's business relies on its proprietary platform for identifying and developing novel TCR-T therapies, making the establishment and maintenance of intellectual property protection crucial. Competition from other companies developing similar therapies, or the inability to effectively protect its intellectual property, could limit TScan's market share and profitability.AI Analysis | Feedback
null
AI Analysis | Feedback
nullAI Analysis | Feedback
TScan Therapeutics (TCRX) is anticipated to drive future revenue growth over the next 2-3 years through the following key initiatives:
- Advancement and Potential Commercialization of TSC-101 for Hematologic Malignancies: The primary driver of future revenue growth is the progression and potential market entry of TSC-101, a T cell receptor-engineered T cell (TCR-T) therapy for hematologic malignancies. TScan Therapeutics plans to initiate a pivotal trial for TSC-101 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the second quarter of 2026. Positive clinical trial results and subsequent regulatory approval would be a significant catalyst for commercial revenue generation. Further, preliminary data has shown 100% relapse-free survival in AML patients treated with TSC-101 at two-year follow-up.
- Expansion of the Hematologic Malignancies Pipeline: TScan is actively expanding its heme malignancies program beyond TSC-101. The company received FDA clearance for Investigational New Drug (IND) applications for TSC-102-A01 and TSC-102-A03, designed to target CD45 in patients with specific HLA types. A Phase 1 study for these additional candidates is slated to begin in the second half of 2026, broadening the potential patient population and future revenue streams within this prioritized therapeutic area.
- Strategic Collaboration and Licensing Agreements: Collaboration and licensing agreements are expected to be a continued source of revenue. In 2025, TScan Therapeutics reported $10.3 million in collaboration and license revenue, primarily driven by timing of activities under its collaboration with Amgen. While a prior collaboration agreement with Novartis concluded in March 2023, ongoing and new partnerships leveraging TScan's proprietary T-cell receptor discovery platform could provide upfront payments, research funding, milestone payments, and royalties, contributing to revenue growth.
AI Analysis | Feedback
Share Repurchases
TScan Therapeutics (TCRX) has made no share repurchases over the last 3-5 years.
Share Issuance
- As of December 31, 2025, TScan Therapeutics had 52,625,035 shares of voting common stock and 4,276,588 shares of non-voting common stock outstanding.
- Including common stock and pre-funded warrants, the pro forma outstanding shares were 129,913,390 as of December 31, 2025.
- In January 2026, officers Dworak Leiden and Zoran Zdraveski received stock option grants for 100,000 and 350,000 shares, respectively, with an exercise price of $1.12 per share.
Inbound Investments
- Revenue, primarily from its collaboration agreement with Amgen, increased to $10.3 million for the full-year 2025, up from $2.8 million in 2024.
- The company held $152.4 million in cash and cash equivalents as of December 31, 2025, which is projected to fund operations into the second half of 2027.
Capital Expenditures
- Capital expenditures for 2025 amounted to $4.4 million.
- Research and development (R&D) expenses were $114.2 million for the full-year 2025, an increase from $107.4 million in 2024, reflecting a significant allocation towards its clinical programs.
- TScan anticipates the need for substantial additional funding to complete the development and potential commercialization of its product candidates.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| TScan Therapeutics Earnings Notes | 12/16/2025 | |
| TScan Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to TCRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 32.84 |
| Mkt Cap | 3.3 |
| Rev LTM | 166 |
| Op Inc LTM | -267 |
| FCF LTM | -238 |
| FCF 3Y Avg | -204 |
| CFO LTM | -219 |
| CFO 3Y Avg | -196 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.7% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 17.7% |
| QoQ Delta Rev Chg LTM | 5.2% |
| Op Inc Chg LTM | 4.8% |
| Op Inc Chg 3Y Avg | -0.1% |
| Op Mgn LTM | -401.4% |
| Op Mgn 3Y Avg | -1,590.4% |
| QoQ Delta Op Mgn LTM | 13.1% |
| CFO/Rev LTM | -349.0% |
| CFO/Rev 3Y Avg | -1,301.7% |
| FCF/Rev LTM | -356.3% |
| FCF/Rev 3Y Avg | -1,342.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.3 |
| P/S | 10.7 |
| P/Op Inc | -2.3 |
| P/EBIT | -2.4 |
| P/E | -2.5 |
| P/CFO | -2.5 |
| Total Yield | -17.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -14.6% |
| D/E | 0.2 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.6% |
| 3M Rtn | 2.4% |
| 6M Rtn | 9.5% |
| 12M Rtn | 26.4% |
| 3Y Rtn | -24.0% |
| 1M Excs Rtn | -6.5% |
| 3M Excs Rtn | -2.6% |
| 6M Excs Rtn | 3.0% |
| 12M Excs Rtn | -2.4% |
| 3Y Excs Rtn | -89.8% |
Price Behavior
Price Behavior
| Market Price | $1.21 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 07/16/2021 | |
| Distance from 52W High | -52.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.11 | $1.38 |
| DMA Trend | down | up |
| Distance from DMA | 8.9% | -12.5% |
| 3M | 1YR | |
| Volatility | 80.2% | 88.8% |
| Downside Capture | 1.66 | 1.81 |
| Upside Capture | 319.61 | 219.47 |
| Correlation (SPY) | 44.4% | 31.6% |
TCRX Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.94 | 1.89 | 2.39 | 2.45 | 2.26 | 1.26 |
| Up Beta | 1.04 | 1.09 | 2.02 | 2.53 | 2.49 | 1.32 |
| Down Beta | 31.89 | 1.16 | 1.25 | 1.43 | 0.48 | 0.98 |
| Up Capture | 254% | 324% | 408% | 251% | 389% | 128% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 18 | 24 | 50 | 111 | 332 |
| Down Capture | -114% | 194% | 219% | 226% | 193% | 110% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 22 | 33 | 63 | 123 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCRX | |
|---|---|---|---|---|
| TCRX | -23.4% | 89.1% | 0.11 | - |
| Sector ETF (XLV) | 6.8% | 15.7% | 0.23 | 24.8% |
| Equity (SPY) | 27.8% | 12.5% | 1.73 | 31.8% |
| Gold (GLD) | 40.6% | 27.2% | 1.23 | 5.0% |
| Commodities (DBC) | 50.1% | 18.0% | 2.16 | -7.3% |
| Real Estate (VNQ) | 11.0% | 13.4% | 0.53 | 20.8% |
| Bitcoin (BTCUSD) | -17.3% | 42.2% | -0.34 | 25.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCRX | |
|---|---|---|---|---|
| TCRX | -34.0% | 98.8% | 0.01 | - |
| Sector ETF (XLV) | 5.2% | 14.6% | 0.18 | 12.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 14.7% |
| Gold (GLD) | 20.2% | 17.9% | 0.92 | 4.8% |
| Commodities (DBC) | 14.0% | 19.1% | 0.60 | -0.1% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 11.5% |
| Bitcoin (BTCUSD) | 7.9% | 56.2% | 0.35 | 7.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCRX | |
|---|---|---|---|---|
| TCRX | -18.8% | 98.8% | 0.01 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 12.7% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 14.7% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 4.8% |
| Commodities (DBC) | 9.6% | 17.7% | 0.45 | -0.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 11.5% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | 7.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/4/2026 | 4.3% | 14.0% | -0.5% |
| 11/12/2025 | -2.5% | -18.8% | -17.2% |
| 8/12/2025 | 3.7% | 11.2% | 14.3% |
| 3/5/2025 | -5.0% | -9.9% | -37.1% |
| 11/12/2024 | -4.9% | -26.3% | -46.0% |
| 8/12/2024 | 1.4% | -3.0% | 0.0% |
| 3/6/2024 | 1.7% | -3.8% | 0.9% |
| 11/9/2023 | -0.9% | 9.4% | 50.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 5 | 5 |
| # Negative | 8 | 10 | 10 |
| Median Positive | 1.7% | 9.4% | 12.1% |
| Median Negative | -3.7% | -14.4% | -26.0% |
| Max Positive | 5.4% | 14.0% | 50.8% |
| Max Negative | -21.2% | -30.9% | -53.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Prior: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lynx1, Capital Management LP | See footnote | Buy | 12232025 | 0.90 | 6,232 | 5,602 | 7,208,412 | Form | |
| 2 | Lynx1, Capital Management LP | See footnote | Buy | 12232025 | 0.90 | 75,500 | 67,950 | 7,211,624 | Form | |
| 3 | Lynx1, Capital Management LP | See footnote | Buy | 12232025 | 0.90 | 80,069 | 71,974 | 7,134,943 | Form | |
| 4 | Lynx1, Capital Management LP | See footnote | Buy | 5212025 | 1.20 | 1,200,000 | 1,440,000 | 9,535,369 | Form | |
| 5 | Lynx1, Capital Management LP | See footnote | Buy | 5212025 | 1.20 | 1,388,794 | 1,666,553 | 8,095,369 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.